Melanoma is a severe form of cancer, commonly known as skin cancer. The population residing at higher altitude levels or in the close proximity to the equator, are the most susceptible to melanoma, as the symptoms are prominently initiated post-exposure to Ultraviolet (UV) radiation that results in blistering sunburns. If diagnosed early in stage 0, melanoma can be surgically cured to almost 100%; however, when the disease metastizes in a body, it becomes strenuous to treat it due to the availability of a restricted range of treatment options. The selection of treatment line or systemic drug therapy entirely depends on the stage of melanoma.
Metastatic melanoma is the most severe stage (IV) of skin cancer that occurs when melanoma penetrates the skin deeper to reach various parts of a body, predominantly the subcutaneous tissue layer under the skin, lungs, bones, liver, brain, and lymph nodes. In the most severe case of metastasis, the gastrointestinal tract, adrenal glands, spleen, and heart can also be affected. Currently, only a limited set of therapies are available to promisingly treat burgeoning cases of metastatic melanoma patients. The disease thus requires more efficient and effective treatment options.
Market Dynamics
High incidence of melanoma leading to large patient pool is one major factor driving the global metastatic melanoma therapeutics market growth. Melanoma of the skin is the 19th most prevalent cancer in both men and women, according to the World Cancer Research Fund. Globally, the number of cases reported were nearly 300,000 new cases in 2018, which will boost the growth of global metastatic melanoma therapeutics market.
Key features of the study:
- This report provides in-depth analysis of the global metastatic melanoma therapeutics market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2021-2028), considering 2020 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the metastatic melanoma therapeutics market based on the following parameters – company highlights, types portfolio, key highlights, financial performance, and market strategies
- Key companies covered as a part of this study include Bristol-Myers Squibb Company, Novartis AG, Merck & Co., Inc., Genentech Inc., F. Hoffmann-La Roche AG., Amgen Inc., AstraZeneca, Daiichi Sankyo Company, Limited., AB Sciences., AgonOX, Inc., Eisai Co., Ltd, GlaxoSmithKline, plc., Pfizer, Inc., and Vical, Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global metastatic melanoma therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the metastatic melanoma therapeutics market
Detailed Segmentation:
- Global Metastatic melanoma therapeutics Market, By Therapy:
- Chemotherapy
- Immunotherapy
- Targeted Therapy
- Radiation Therapy
- Surgery
- Global Metastatic melanoma therapeutics Market, By Stages:
- Stage 0
- Stage I
- Stage II
- Stage III
- Stage IV
- Global Metastatic melanoma therapeutics Market, By End User:
- Hospitals
- Specialty Clinics
- Home Healthcare
- Others
- Global Metastatic melanoma therapeutics Market, By Region:
- North America
- By Therapy
- Chemotherapy
- Immunotherapy
- Targeted Therapy
- Radiation Therapy
- Surgery
- By Stages
- Stage 0
- Stage I
- Stage II
- Stage III
- Stage IV
- By End User
- Hospitals
- Specialty Clinics
- Home Healthcare
- Others
- By Country
- Latin America
- By Therapy
- Chemotherapy
- Immunotherapy
- Targeted Therapy
- Radiation Therapy
- Surgery
- By Stages
- Stage 0
- Stage I
- Stage II
- Stage III
- Stage IV
- By End User
- Hospitals
- Specialty Clinics
- Home Healthcare
- Others
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Therapy
- Chemotherapy
- Immunotherapy
- Targeted Therapy
- Radiation Therapy
- Surgery
- By Stages
- Stage 0
- Stage I
- Stage II
- Stage III
- Stage IV
- By End User
- Hospitals
- Specialty Clinics
- Home Healthcare
- Others
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Therapy
- Chemotherapy
- Immunotherapy
- Targeted Therapy
- Radiation Therapy
- Surgery
- By Stages
- Stage 0
- Stage I
- Stage II
- Stage III
- Stage IV
- By End User
- Hospitals
- Specialty Clinics
- Home Healthcare
- Others
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Therapy
- Chemotherapy
- Immunotherapy
- Targeted Therapy
- Radiation Therapy
- Surgery
- By Stages
- Stage 0
- Stage I
- Stage II
- Stage III
- Stage IV
- By End User
- Hospitals
- Specialty Clinics
- Home Healthcare
- Others
- By Country
- GCC
- Israel
- Rest of Middle East
- Africa
- By Therapy
- Chemotherapy
- Immunotherapy
- Targeted Therapy
- Radiation Therapy
- Surgery
- By Stages
- Stage 0
- Stage I
- Stage II
- Stage III
- Stage IV
- By End User
- Hospitals
- Specialty Clinics
- Home Healthcare
- Others
- By Country/Region
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Bristol-Myers Squibb Company
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Novartis AG
- Merck & Co., Inc.
- Genentech Inc.
- Hoffmann-La Roche AG.
- Amgen Inc.
- AstraZeneca
- Daiichi Sankyo Company, Limited.
- AB Sciences.
- AgonOX, Inc.
- Eisai Co., Ltd
- GlaxoSmithKline, plc.
- Pfizer, Inc.
- Vical, Inc.
“*” marked represents similar segmentation in other categories in the respective section.
